$PFE Astellas Phase 3 ARCHES Trial Shows XTANDIÂ Significantly Improved Radiographic PFS in Men with Metastatic HormoneSensitive Prostate Cancer ASCOGU19 httpswww.prnewswire.comnewsreleasesphase3archestrialshowsxtandienzalutamidesignifica

$PFE #Astellas Phase 3 ARCHES Trial Shows XTANDI® Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer #ASCOGU19 https://www.prnewswire.com/news-releases/phase-3-arches-trial-shows-xtandi-enzalutamide-significa

17:03 EST 11 Feb 2019 | Odi Bruckman

$PFE #Astellas Phase 3 ARCHES Trial Shows XTANDI® Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer #ASCOGU19 https://www.prnewswire.com/news-releases/phase-3-arches-trial-shows-xtandi-enzalutamide-significantly-improved-radiographic-progression-free-survival-in-men-with-metastatic-hormone-sensitive-prostate-cancer-300793479.html …

More From BioPortfolio on "$PFE #Astellas Phase 3 ARCHES Trial Shows XTANDI® Significantly Improved Radiographic PFS in Men with Metastatic Hormone-Sensitive Prostate Cancer #ASCOGU19 https://www.prnewswire.com/news-releases/phase-3-arches-trial-shows-xtandi-enzalutamide-significa"